Journal of Medical Physics
 Home | Search | Ahead of print | Current Issue | Archives | Instructions | Subscription | Login  The official journal of Association of Medical Physicists of India      
 Users online: 113  Home  EMail this page Print this page Decrease font size Default font size Increase font size 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 45  |  Issue : 1  |  Page : 24-35

Validation of PRIMO monte carlo model of clinac®ix 6mv photon beam


1 Department of Physics, Noorul Islam Centre For Higher Education, Kumaracoil, Kanyakumari, Tamil Nadu; Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
2 Department of Physics, Noorul Islam Centre For Higher Education, Kumaracoil, Kanyakumari, Tamil Nadu, India
3 Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India

Correspondence Address:
Mr. B Sarin
C Block, Room No. 3, Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram - 695 011, Kerala
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmp.JMP_75_19

Rights and Permissions

Purpose: This study aims to model 6MV photon of Clinac®iX linear accelerator using PRIMO Monte Carlo (MC) code and to assess PRIMO as an independent MC-based dose verification and quality assurance tool. Materials and Methods: The modeling of Clinac®iX linear accelerator has been carried out by using PRIMO simulation software (Version 0.3.1.1681). The simulated beam parameters were compared against the measured beam data of the Clinac®iX machine. The PRIMO simulation model of Clinac®iX was also validated against Eclipse® Acuros XB dose calculations in the case of both homogenous and inhomogeneous mediums. The gamma analysis method with the acceptance criteria of 2%, 2 mm was used for the comparison of dose distributions. Results: Gamma analysis shows a minimum pass percentage of 99% for depth dose curves and 95.4% for beam profiles. The beam quality index and output factors and absolute point dose show good agreement with measurements. The validation of PRIMO dose calculations, in both homogeneous and inhomogeneous medium, against Acuros® XB shows a minimum gamma analysis pass rate of 99%. Conclusions: This study shows that the research software PRIMO can be used as a treatment planning system-independent quality assurance and dose verification tool in daily clinical practice. Further validation will be performed with different energies, complex multileaf collimators fields, and with dynamic treatment fields.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed22    
    Printed6    
    Emailed0    
    PDF Downloaded5    
    Comments [Add]    

Recommend this journal